EF Hutton analyst Elemer Piros initiated coverage of Atai Life Sciences with a Buy rating and $23 price target. Atai has assembled one of the largest drug portfolios in four years, including five psychedelic programs, to revolutionize the treatment of mental health, Piros tells investors in a research note. The analyst calls the company the "undisputed leader in mental health."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ATAI:
- The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital
- Rising High: Exclusive talk with market research firm Brightfield Group
- Here’s What You Missed in Cannabis This Week
- Atai Life Sciences names Sahil Kirpekar Chief Business Officer
- ‘Too Cheap to Ignore’: Cathie Wood Snaps Up These 2 Stocks Under $5
